Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Public ClinicalTrials.gov record NCT02847728. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an observational, multicenter study in participants treated with nivolumab for the approved indications of melanoma and Lung cancer in Australia, the EU, Switzerland, the United Kingdom (UK), and the United States (US). The targeted countries in the EU for study participation include Austria, Belgium, Czech Republic, France, Germany, Hungary, Italy, Poland, and Spain. Study objectives are to assess the safety experience, survival, adverse event management, and outcomes of adverse events associated with nivolumab in routine oncology care facilities.
Study identification
- NCT ID
- NCT02847728
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 1,189 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 28, 2016 (Actual)
- Primary completion
- Mar 31, 2024 (Actual)
- Completion
- Mar 31, 2024 (Actual)
- Last update posted
- Jun 3, 2024
2016 – 2024
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 1909 | Palm Springs | California | 92262 | — |
| Local Institution - 1912 | Jacksonville | Florida | 32204 | — |
| Local Institution - 1907 | Lake City | Florida | 32024 | — |
| Local Institution - 1901 | Park Ridge | Illinois | 60068 | — |
| Local Institution - 1910 | Alexandria | Louisiana | 71301 | — |
| Local Institution - 1906 | Tupelo | Mississippi | 38801 | — |
| Local Institution - 1908 | Kansas City | Missouri | 64108 | — |
| Local Institution - 1911 | Morristown | New Jersey | 07962 | — |
| Local Institution - 1902 | Bethlehem | Pennsylvania | 18015 | — |
| Local Institution - 1913 | Hilton Head Island | South Carolina | 29926 | — |
| Local Institution - 1915 | El Paso | Texas | 79920 | — |
| Local Institution - 1905 | Fort Sam Houston | Texas | 78234-6200 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 82 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02847728, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 3, 2024 · Synced Oct 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02847728 live on ClinicalTrials.gov.